NewAmsterdam Pharma Company N.V.
General ticker "NAMSW" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $3.6B (TTM average)
NewAmsterdam Pharma Company N.V. follows the US Stock Market performance with the rate: 23.7%.
Estimated limits based on current volatility of 4.7%: low 16.53$, high 18.16$
Factors to consider:
- Earnings expected soon, date: nan
- Total employees count: 100 (+47.1%) as of 2025
- Top business risk factors: Limited operating history, Manufacturing and quality control, Regulatory and compliance, Labor/talent shortage/retention, Strategic risks and growth management
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [13.29$, 30.35$]
- 2026-12-31 to 2027-12-31 estimated range: [9.18$, 22.45$]
Financial Metrics affecting the NAMSW estimates:
- Negative: with PPE of -12.2 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -5.66 <= 0.30
- Positive: Inventory ratio change, % of -3.40 <= -0.76
- Negative: negative Net income
- Negative: negative Industry operating income (median)
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term NAMSW quotes
Long-term NAMSW plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $14.09MM | $45.56MM | $22.50MM |
| Operating Expenses | $197.06MM | $221.85MM | $248.19MM |
| Operating Income | $-182.97MM | $-176.29MM | $-225.68MM |
| Non-Operating Income | $6.06MM | $-65.31MM | $21.86MM |
| R&D Expense | $159.42MM | $151.41MM | $141.83MM |
| Income(Loss) | $-176.91MM | $-241.60MM | $-203.82MM |
| Taxes | $0.03MM | $-0.00MM | $0.00MM |
| Net Income(Loss)* | $-176.94MM | $-241.60MM | $-203.82MM |
| Stockholders Equity | $288.39MM | $757.50MM | $683.43MM |
| Assets | $347.10MM | $864.62MM | $769.28MM |
| Operating Cash Flow | $-141.22MM | $-158.56MM | $-147.78MM |
| Capital expenditure | $0.02MM | $0.67MM | $0.25MM |
| Investing Cash Flow | $-0.02MM | $-62.85MM | $-174.92MM |
| Financing Cash Flow | $8.91MM | $659.51MM | $29.52MM |
| Earnings Per Share** | $-2.15 | $-2.56 | $-1.78 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.